https://scholars.lib.ntu.edu.tw/handle/123456789/538773
標題: | Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase | 作者: | Cortes J. Kim D.-W. Raffoux E. Martinelli G. Ritchie E. Roy L. Coutre S. Corm S. Hamerschlak N. JIH-LUH TANG Hochhaus A. Khoury H.J. Brümmendorf T.H. Michallet M. Rege-Cambrin G. Gambacorti-Passerini C. Radich J.P. Ernst T. Zhu C. Van Tornout J.M.A. Talpaz M. |
公開日期: | 2008 | 出版社: | Nature Publishing Group | 卷: | 22 | 期: | 12 | 起(迄)頁: | 2176-2183 | 來源出版物: | Leukemia | 摘要: | Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in ?6% of patients, except febrile neutropenia (15%). Cytopenias were noted in the majority of patients, and were manageable with dose interruptions/reductions. Dasatinib is associated with a promising rate of response in this high-risk population. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-57849159300&doi=10.1038%2fleu.2008.221&partnerID=40&md5=5a1a5edebd5e70b448ea37de98581934 https://scholars.lib.ntu.edu.tw/handle/123456789/538773 |
ISSN: | 0887-6924 | DOI: | 10.1038/leu.2008.221 | SDG/關鍵字: | alpha interferon; BCR ABL protein; dasatinib; diuretic agent; imatinib; steroid; adolescent; adult; aged; anemia; anorexia; article; asthenia; blood toxicity; cancer survival; chemotherapy induced emesis; chronic myeloid leukemia; clinical trial; cohort analysis; controlled clinical trial; controlled study; coughing; cytogenetics; cytopenia; diarrhea; digestive system hemorrhage; disease course; disease free survival; disease severity; drug dose escalation; drug dose reduction; drug efficacy; drug eruption; drug fever; drug induced headache; drug response; drug safety; drug tolerability; drug withdrawal; epistaxis; fatigue; febrile neutropenia; female; fluid retention; follow up; high risk patient; human; human cell; leukopenia; major clinical study; male; nausea; neutropenia; outcome assessment; overall survival; peripheral edema; phase 2 clinical trial; pleura effusion; priority journal; side effect; stem cell transplantation; survival time; thrombocytopenia |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。